EMD
vs
S
S&P/ASX 300
EMD
Over the past 12 months, EMD has significantly outperformed S&P/ASX 300, delivering a return of +104% compared to the S&P/ASX 300's +17% growth.
Stocks Performance
EMD vs S&P/ASX 300
Performance Gap
EMD vs S&P/ASX 300
Performance By Year
EMD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Emyria Ltd
Glance View
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
